Securities Lawsuit Filed Against Replimune Group, Inc.

A class action securities lawsuit was filed against Replimune Group, Inc. (NASDAQ: REPL) in response to alleged securities fraud between November 22, 2024, and July 21, 2025. The lawsuit claims that defendants made false statements and/or concealed material issues related to the IGNYTE trial, which resulted in the FDA deeming the trial inadequate and not well-controlled. This has allegedly led to significant losses for shareholders.

Key Takeaways:

• The lawsuit alleges that Replimune Group, Inc. defendants made false statements and/or concealed material issues related to the IGNYTE trial, which resulted in the FDA's negative assessment.
• The filed complaint alleges that defendants' statements about the company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
• The lawsuit seeks to recover losses of shareholders who were adversely affected by the alleged securities fraud.
• Levi & Korsinsky, a nationally-recognized securities litigation firm, is representing investors in this case.
• The firm has secured hundreds of millions of dollars for aggrieved shareholders and has a track record of winning high-stakes cases.

Statistics:

• The litigation spans approximately 9 months, from November 22, 2024, to July 21, 2025.
• The lawsuit alleges that Replimune Group, Inc. suffered from material issues that affected the IGNYTE trial.
• The firm of Levi & Korsinsky has over 70 employees serving their clients.

Sources:

• https://zlk.com/pslra-1/replimune-group-inc-lawsuit-submission-form?prid=166224&wire=5&utm_campaign=7
• https://www.newsfilecorp.com/release/265757